Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China
|
MSCI China Small-Cap
|
Hang Seng Index
|
Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Hengrui Pharma

Kailera Therapeutics IPO

Drug spin-off trend gains traction with IPO by Hengrui offshoot

A company set up to develop Hengrui Pharma’s weight-loss drugs has made a strong debut on the U.S. equity market, building confidence in the “NewCo” business model Key Takeaways: Hengrui’s…
April 23, 2026
1276.HK
600276.SHG

Recent Articles

Kailera Therapeutics IPO
April 23, 2026

Drug spin-off trend gains traction with IPO by Hengrui offshoot

1276.HK
600276.SHG

RELATED ARTICLES

  1. Keymed set up a “NewCo” company
    April 2, 2026
    A healthy return: drug spin-off nets Keymed up to $320 million
    2162.HK
  2. December 18, 2025
    Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
    2196.HK
    600196.SHG
  3. January 15, 2026
    InSilico lands drug discovery deal after Hong Kong IPO
    3696.HK
  4. January 2, 2026
    Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2026 Bamboo Works. All rights reserved.